4th Annual Gene Therapy Immunogenicity Summit 2023

The challenges posed by the immune response is one of the biggest obstacles to developing safe, effective, and durable gene therapies. Over the last two decades, drug developers have observed and begun developing solutions to a wide range of immune responses to AAV vectors.

The 4th Annual Gene Therapy Immunogenicity Summit is your opportunity to connect with likeminded peers from gene therapy drug developers, along with leading academics, regulators, and key service providers, all making strides with improving risk assessments, monitoring, and mitigating against AAV gene therapy immunogenicity.

Time: 08:30 – 16:00

Venue details: Hilton Boston Back Bay, 40 Dalton Street, Boston, Massachusetts, 02115, United States

Prices:
USD 1298.00 – USD 5297.00

Speakers: Adrian Veres, Co-Founder, Dyno Therapeutics, Benjamin Greenberg, Vice Chair, Translational Research; Director, Transverse Myelitis, NMO and CONQUER Program, University of Texas Southwestern Medical Center, and more.